Background
Potential triggers of rheumatoid arthritis (RA) include cytokines and dysregulation of the cytokine network can result in uncontrolled inflammation leading to rheumatoid arthritis [1].

TNF-α and IL-6 are key inflammatory cytokines implicated in the pathogenesis of RA [2]. Targeted blockade of TNF-α and IL-6 is effective for refractory RA patients [3]. TNF-α secretion from synovial macrophages may be a major player in rheumatoid synovitis [4]. However, TNF-α-triggered cytokine signaling in rheumatoid inflammation is not completely understood, and the elucidation of endogenous positive and negative modulators of cytokine signaling is needed for a more effective therapeutic approach [5].

miRNAs play important roles in inflammatory processes and miRNA-based gene therapies targeting deregulated miRNAs have great potential [6]. Important features of miRNAs include their redundancy to target sequences in the 3′-untranslated regions of messenger RNAs [7]. These unique properties prompted us to speculate that miRNAs can regulate the cytokine-network during the pathogenesis of RA [8]. Recent studies have identified altered miRNA expression in RA patients [9]. These investigations demonstrated increased expression of miR-155 and miR-146a in both rheumatoid synovial fibroblasts and synovial tissues compared to osteoarthritis (OA) patients [10]. These findings suggest that altered miRNA expression contributes to the rheumatoid inflammatory process by affecting resident synovial cells of the rheumatoid joint and their cytokine network [11].
We hypothesized that TNF-α modulates the inflammatory signaling pathway by regulating other cytokines via miRNAs.

Methods

Reagents
Phospho-specific and pan antibodies against JAK-1 (Y1022/1023), JAK-2 (Y1007/1008), STAT-1 (Y701) and STAT-3 (Y705) were purchased from Cell Signaling Technology (Beverly, MA).

Preparation of RASFs
Synovial tissue was obtained from patients with RA at the time of total joint replacement. Synovium was minced and incubated with 1 mg/ml collagenase type VIII (Sigma-Aldrich, St. Louis, MO) in serum-free RPMI 1640 medium (Life Technologies, Grand Island, NY) for 1 h at 37 °C, filtered, extensively washed, and cultured in DMEM (Life Technologies) supplemented with 10% FBS (Gibco, 10270106) in 12 well flat bottom cell culture plates (Falcon® #353043). Synovial fibroblasts (SFs) were used from passages 4 through 7th. The expression of CD45 on synovial fibroblasts was measured by flow cytometry using a Coulter Epics XL flow cytometer (Beckman Coulter, Brea, CA, USA) using Expo32 ADC analysis software (Beckman Coulter) and we confirmed that synovial fibroblasts were negative for CD45 (<1% CD45-positive). Synovial tissue samples were obtained from three female patients (mean age: 62.3 years old) with RA during synovectomy.

Microarray analysis for miRNAs
Small RNA was isolated from RASFs using QIAzol reagent according to the manufacturer’s instructions (Qiagen, Hilden, Germany). Microarray analysis was performed to evaluate miRNA expression patterns in RASFs using 3D-Gene miRNA Oligo chips according to the manufacturer’s instructions (Toray Industries, Inc. Tokyo, Japan). Small RNAs from RASFs were labelled using the miRCURY LNA™ microRNA Array Power Labelling Kit (Exiqon, Palm Beach FL, USA) and analyzed using 3D-Gene miRNA Oligo chips Ver. 17.0 (Toray Industries Inc.) containing more than 1700 antisense probes printed in duplicate spots, according to the manufacturer’s instructions. Signals were analyzed using the 3D-Gene Scanner 3000 (Toray Industries Inc. Tokyo, Japan) and analyzed using 3D-Gene Extraction software (Toray Industries Inc., Tokyo, Japan). A relative expression level of a given miRNA was calculated by comparing the signal intensities of the valid spots throughout the microarray experiments. The Normalized data were globally normalized per array, such that the median of the signal intensity was adjusted to 25.

Quantitative PCR (qPCR) analysis for miR-155-5p
Small RNA was isolated from RASFs using QIAzol reagent according to the manufacturer’s instructions (Qiagen, Limburg, The Netherlands). The RNA quality was assessed by microcapillary electrophoresis (2100 BioAnalyser, Agilent Technologies, Waldbronn, Germany). cDNA was reverse transcribed from 2.5 μl RNA using the TaqMan miRNA reverse transcription kit (TaqManR MicroRNA Reverse Transcription Kit, AppliedBiosystems®). qRT-PCR for the detection of hsa-miR-155-5p was carried out in 20 μl PCR reactions using the TaqMan MicroRNA assay with the StepOnePlus detection system (Applied Biosystems) at 50 °C for 2 min then 95 °C for 10 min, followed by 40 cycles of 95 °C for 15 s and 60 °C for 1 min. Expression of RNU6B were used as internal controls to normalize each mRNA and miRNA expression, respectively. The comparative threshold cycle (Ct) method was used for relative quantification of the miRNA. Differences in the Ct values (ΔCt) between the tested miR-155 and RNU6B cDNA were calculated to determine the relative expression levels, using the following formula: ΔΔCt = ΔCt of the tested sample—ΔCt of the control sample. The value of each control sample was set at 1 and was used to calculate the fold change in target genes.

Transfection of miR-155
RASFs (n = 3) were transfected in 12-well plates (5 × 10⁴ cells/well) using Lipofectamine 2000 reagent (Invitrogen) according to the manufacturer’s protocol, with 100 nM (final concentration) of synthetic miR-155 precursory molecule (miR-155 mimics) or a scrambled control (negative control, Thermo Fisher Scientist Inc. Waltham, MA, USA).

Cell lysis and Western blotting
Micro-RNAs-transfected-RA-FLS were serum-starved (12 h), then stimulated with IL-6 (50 ng/ml) and sIL-6R (50 ng/ml) for indicated time and the cells were washed by ice-cold PBS and lysed with RIPA Buffer (Sigma-Aldrich, R0278) supplemented with 1.0 mM sodium orthovanadate, 10 μg/ml aprotinin and 10 μg/ml leupeptin for 20 min at 4 °C. Insoluble material was removed by centrifugation at 15,000×g for 15 min at 4 °C. The supernatant was saved and the protein concentration was determined using the Bio-Rad protein assay kit (Bio Rad, Hercules, CA, 5000001). An identical amount of protein (30 μg) for each lysate was subjected to 10% SDS–polyacrylamide gel electrophoresis, and then transferred to a nitrocellulose membrane. Western blot analysis using phospho-specific anti-JAKs, and STAT’s antibodies was performed with an ECL advance western blotting detection kit (GE Health RPN2135).
Statistical analysis
Differences between groups were examined for statistical significance using Student’s two-tailed t-test. P values less than 0.05 were considered statistically significance.

Findings
miRNA expression profile in TNF-α-activated RASFs
As an initial experiment, to determine which miRNAs are expressed in TNF-α-exposed rheumatoid synoviocytes (RASFs), we isolated miRNAs from TNFα-treated or untreated RASFs and screened them against a miRNA array consisting of 3450 miRNAs. A comparison between TNF-α stimulated and unstimulated RASFs identified 10 miRNAs that were up-regulated by more than twofold (Table 1). Among these isolated miRNAs, miR-155-5p was most highly up-regulated in TNF-α-stimulated RASFs (Table 1; Fig. 1). To confirm the array results, we examined miRNA-155 expression in TNF-α-stimulated RASFs isolated from three RA patients using quantitative real-time PCR using. We treated the RASFs in vitro with TNF-α (50 ng/ml) for 3–24 h, and then assessed miRNA-155 expression by real-time PCR. We observed significant up-regulation of miR-155 6 h after TNF-α stimulation that reached a plateau after 12 h (Fig. 2a). Additionally, TNFα-stimulated RASFs secreted miR-155-5p into the culture medium in a dose-dependent manner (Fig. 2b).

Table 1 A differentially expression miRNAs between control and TNFα-stimulated RASFs

| No. | miR_name     | Fold change | No. | miR_name     | Fold change |
|-----|--------------|-------------|-----|--------------|-------------|
| 1   | hsa-miR-155-5p | 5.63        | 1   | hsa-miR-637 | 0.35        |
| 2   | hsa-miR-2467-3p | 4.17        | 2   | hsa-miR-4675 | 0.35        |
| 3   | hsa-miR-933    | 3.07        | 3   | hsa-miR-4746-3p | 0.40 |
| 4   | hsa-miR-4521   | 2.92        | 4   | hsa-miR-6131 | 0.41        |
| 5   | hsa-miR-4708-3p | 2.73        | 5   | hsa-miR-222-5p | 0.43     |
| 6   | hsa-miR-26b-3p | 2.57        | 6   | hsa-miR-1298-5p | 0.44 |
| 7   | hsa-miR-3193   | 2.51        | 7   | hsa-miR-6875-5p | 0.47 |
| 8   | hsa-miR-4313   | 2.46        | 8   | hsa-miR-6792-5p | 0.47 |
| 9   | hsa-miR-6715b-5p | 2.44       | 9   | hsa-miR-6858-5p | 0.48 |
| 10  | hsa-miR-33a-5p | 2.42        | 10  | hsa-miR-1470 | 0.48        |

miR-155-5p regulates IL-6-mediated signaling in RASFs
To investigate the roles of miR-155-5p in IL-6-mediated signal transduction pathway, we transfected RASFs with miR-155 mimic before stimulation with IL-6 plus soluble IL-6 receptor (sIL-6R). RASFs pretreated with miR-155 were stimulated by IL-6 [IL-6 plus soluble IL-6 receptor (sIL-6R)] for 20 min. The phosphorylation of JAK1/2 and STAT1/STAT3 was investigated by immunoblot analysis. IL-6 stimulation induced JAK2 and STAT3 phosphorylation in RASFs, whereas, JAK1 and STAT1 phosphorylation was barely detected. The levels of phosphorylation of JAK2 and STAT3, which were rapidly induced by IL-6 stimulation, were down-regulated in RASFs transfected with miR-155 mimics. Whereas, the phosphorylation levels of JAK2/STAT3 were not affected in RASFs transfected with control mimics or miR-155 inhibitors (Fig. 3). These data indicate that TNF-α-induced over-expression of miR-155 resulted in the down-regulation of IL-6-induced JAK2/STAT3 activation in RASFs.

We then investigated the regulation of miR-155 expression by another cytokine, IL-6. In IL-6 trans-signaling system, IL-6/soluble IL-6 receptor (sIL-6R) complex resulted in activation of JAK/STAT pathway in rheumatoid synovial fibroblasts [12]. It was also demonstrated that without sIL-6R, IL-6 stimulation alone could not induce various genes expressions in rheumatoid synovial fibroblast [13]. Therefore, we stimulated synovial fibroblast with IL-6 in the presence of sIL-6R at the optional concentrations as described previously [13]. As shown in Fig. 2c, miR-155 expression in RASFs was not induced by IL-6 stimulation in the presence of sIL-6R.
Discussion

TNF-α is an important pathogenic cytokine in RA and epigenetic modulation by TNF-α could be implicated in rheumatoid synovitis [14]. The miRNA network is emerging as an important factor in the pathophysiology of autoimmune and inflammatory disorders [11]. Previous studies have reported aberrant expressions of miRNAs in blood or joint tissues and suggested their pathogenic roles in the inflammatory processes in RA [8]. The principal purpose of this study was to determine the mechanism and biological consequences of TNF-α against IL-6 signaling in RASFs. The results demonstrated an interaction relationship between TNF-α and subsequent IL-6 signaling, which may be attributable to TNF-α-induced miR-155-5p. This TNF-α-mediated epigenetic modulation may contribute to the cross-regulation between TNF-α and IL-6.

IL-6 is a pivotal proinflammatory factor in rheumatoid synovitis [15]. However, the mechanism by which IL-6 signaling is regulated and the role of TNF-α in this cytokine pathway in the rheumatoid synovium is not completely understood. Here, we have identified miR-155 as an important player in IL-6-mediated signal transduction pathway of rheumatoid synovial fibroblasts. miR-155, a typical multi-functional miRNA, is emerging as a novel regulator involved in inflammatory signal pathway [16]. To investigate the roles of miR-155 in IL-6-mediated signal transduction pathway, we transfected rheumatoid...
synovial fibroblasts with miR-155 mimic before stimulation with IL-6 plus soluble IL-6 receptor (sIL-6R). Our results demonstrated that miR-155 over-expression regulates IL-6 signaling by preventing JAK2/STAT3 activation in rheumatoid synovial fibroblasts. This constitutes a negative-feedback loop that regulates the persistent IL-6-mediated inflammatory cascades in rheumatoid synovitis.

miR-155, a typical multi-functional miRNA, is emerging as a novel regulator involved in inflammatory signal pathway [16]. Diverse cellular activities of miR-155 have been described, including involvement in oncogenesis [17]. McInnes et al. demonstrated that miR-155 is up-regulated in rheumatoid synovial tissues and that this up-regulation targeted an inhibitor of inflammation, SHIP-1, which leads to increased levels of proinflammatory cytokines [18]. The fact that miR-155 expression is induced by TNF-α suggests that miR-155 modulates TNF-α-triggered inflammatory cascades in rheumatoid synovitis. We have demonstrated that miR-155 could be implicated with IL-6 signaling pathway by suppressing JAK2/STAT3 activation in RASFs. During the interaction between the TNF-α and IL-6, up-regulated miR-155 expression in TNF-α-induced rheumatoid synovium may negatively regulate IL-6-triggered proinflammatory pathways by preventing JAK2/STAT3 activation. Up-regulated miR-155 controls the expression of MMP-3 and MMP-1 in rheumatoid synovial cells suggesting that miR-155 may be involved in the modulation of rheumatoid inflammatory processes [10]. Our data also suggest that miR-155 might provide a negative feedback loop in the IL-6-mediated inflammatory cascade in rheumatoid inflammatory processes.

Intracellular signaling pathways, that concurrently activated by the inflammatory stimulus, often interact with one another cross-regulatory feedback mechanism [19]. Normally, JAK/STAT pathway induces the expression of SOCS1, which turns off IL-6 signaling by acting through the tyrosine motif 759 of gp130 and blocks JAK and subsequent STAT3 activation [20]. Epigenetic silencing of SOCS1 via miR-155 over-expression was shown to permit constitutive IL-6/STAT3 signaling in lymphoid cells [21]. In contrast, miR-155 was demonstrated to be a part of negative feedback loop in inflammatory cytokine networks. For example, miR-155 expression negatively regulates the inflammatory cytokines cascades by inhibiting TAK1-binding protein 2 (TAB 2) [22]. The mechanism by which IL-6 signaling is regulated by miR-155 in the RASFs is not elucidated in this study and further investigations should be needed.

**Conclusion**

Our data demonstrates that TNF-α is a potent inducer of miR-155 in RASFs. Furthermore, miR-155 over-expression in rheumatoid synoviocytes resulted in the inhibition of IL-6-mediated JAKs/STAT3 activation. These findings suggest that the epigenetic cross-regulatory mechanism exists in the interaction of TNF-α/IL-6 of rheumatoid synovial inflammation.

**Abbreviations**

IL-6: interleukin-6; JAK: Janus kinases; miRNAs: microRNAs; RASFs: rheumatoid synovial fibroblasts; STAT: signal transducer and activator of transcription; TNF-α: tumor necrosis factor-α.

**Authors’ contributions**

KM, HK, CK, TM and TA performed the study, analyzed, interpreted the data; KM drafted the paper; YJ performed the statistical analysis; NI, YI, KK, TN, TK and AK participated in coordination of experimental work. All authors read and approved the final manuscript.

**Author details**

1 Department of Rheumatology, Fukushima Medical University, Hikarigaoka 1, Fukushima 960-1295, Japan. 2 Department of Rheumatology and Clinical Research Center, NHO Nagasaki Medical Center, Omura, Nagasaki, Japan. 3 Department of Orthopedics, Clinical Research Center, NHO Nagasaki Medical Center, Omura, Nagasaki, Japan. 4 Department of Rheumatology, Shinto Kumamoto Hospital, Kumamoto, Kumamoto, Japan. 5 Department of Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Nagasaki, Japan.

**Acknowledgements**

This work was supported by a Grant from the Japan Society for the Promotion of Science (Grant-in-Aid for Scientist Research C26461481).

**Competing interests**

The authors declare that they have no competing interests.

**Availability of data and materials**

The datasets used and analysed during the current study available from the corresponding author on reasonable request.

**Consents to publish**

Not applicable.

**Ethical approval and consent to participate**

This study was approved by the Ethics Committees Nagasaki Medical Center (No. 17063) and written informed consent was obtained from each individuals.

**Funding**

The study was supported by the Practical Research Project for Rare/Intractable Diseases from Japan Agency for Medical Research and Development, AMED.

**Publisher’s Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 8 November 2016   Accepted: 29 July 2017

Published online: 14 August 2017
References

1. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011;365(23):2205–19.
2. Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol. 1996;14:397–440.
3. Feldmann M, Maini RN. Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? Annu Rev Immunol. 2001;19:163–96.
4. Choy E. Understanding the dynamics: pathways involved in the pathogenesis of rheumatoid arthritis. Rheumatol (Oxford). 2012;51(Suppl 3):v3–11.
5. Connell L, McInnes IB. New cytokine targets in inflammatory rheumatic diseases. Best Pract Res Clin Rheumatol. 2006;20(5):865–78.
6. Luo X, Tsai LM, Shen N, Yu D. Evidence for microRNA-mediated regulation in rheumatic diseases. Ann Rheum Dis. 2010;69(Suppl 1):i30–6.
7. Jonas S, Izaurrealde E. Towards a molecular understanding of microRNA-mediated gene silencing. Nat Rev Genet. 2015;16(7):421–33.
8. Churov AV, Oleinik EK, Knip M. MicroRNAs in rheumatoid arthritis: altered expression and diagnostic potential. Autoimmun Rev. 2015;14(11):1029–37.
9. Ammari M, Jorgensen C. Apparally F. Impact of microRNAs on the understanding and treatment of rheumatoid arthritis. Curr Opin Rheumatol. 2013;25(2):225–33.
10. Stanczyk J, Pedrioli DM, Brentano F, Sanchez-Pernaute O, Kolling C, Gay RE, Detmar M, Gay S, Kyburz D. Altered expression of MicroRNA in synovial fibroblasts and synovial tissue in rheumatoid arthritis. Arthritis Rheum. 2008;58(4):1001–9.
11. Pauley KM, Cha S, Chan EK. MicroRNA in autoimmunity and autoimmune diseases. J Autoimmun. 2009;32(3–4):189–94.
12. Deon D, Ahmed S, Tai K, Scaletta N, Herrero C, Lee IH, Krause A, Ivashkiv LB. Cross-talk between IL-1 and IL-6 signaling pathways in rheumatoid arthritis synovial fibroblasts. J Immunol. 2001;167:5395–403.
13. Hashizume M, Hayakawa N, Mihara M. IL-6 trans-signalling directly induces RANKL on fibroblast-like synovial cells and is involved in RANKL induction by TNF-alpha and IL-17. Rheumatology. 2008;47:1635–40.
14. Plant D, Wilson AG, Barton A. Genetic and epigenetic predictors of responsiveness to treatment in RA. Nat Rev Rheumatol. 2014;10(8):329–37.
15. Fonseca JE, Santos MJ, Canhão H, Choy E. Interleukin-6 as a key player in systemic inflammation and joint destruction. Autoimmun Rev. 2009;8(7):538–42.
16. Vigorito E, Kohlihaa S, Lu D, Leyland R. miR-155: an ancient regulator of the immune system. Immunol Rev. 2013;253(1):146–57.
17. Elton TS, Selemion H, Elton SM, Parinandi NL. Regulation of the MIR155 host gene in physiological and pathological processes. Gene. 2013;532(1):1–12.
18. Kurowska-Stolarska M, Alivernini S, Ballantine LE, Asquith DL, Millar NL, Gilchrist DS, Reilly J, Ierna M, Fraser AR, Stolarski B, McSharry C, Hueber AJ, Baxter D, Hunter J, Gay S, Liew FY, McInnes IB. MicroRNA-155 as a proinflammatory regulator in clinical and experimental arthritis. Proc Natl Acad Sci USA. 2011;108(27):11193–8.
19. Heinrich PC, Behrmann I, Haan S, Hermanns HM, Müller-Newen G, Schaper F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J. 2003;374(Pt 1):1–20.
20. Yoshimura A, Naka T, Kubo M. SOCS proteins, cytokine signalling and immune regulation. Nat Rev Immunol. 2007;7(8):454–65.
21. Wang P, Hou J, Lin L, Wang C, Liu X, Li D, Ma F, Wang Z, Cao X. Inducible microRNA-155 feedback promotes type I IFN signaling in antiviral innate immunity by targeting suppressor of cytokine signaling 1. J Immunol. 2010;185(10):6226–33.
22. Ceppi M, Pereira PM, Dunand-Sauthier I, Barras E, Reith W, Santos MA, Pierre P. MicroRNA-155 modulates the interleukin-1 signaling pathway in activated human monocyte-derived dendritic cells. Proc Natl Acad Sci USA. 2009;106(8):2735–40.